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Detection of the CysSc Fibrosis Carrier in the General Population: 
A Pilot Study 
L. Picci, M. Career an, D. Mar zenta, O. Mar angon, F. Zacchello, M. Scarpa 
Department ofPediatrics University of Padova, Italy 
OJslic Fibrosis (CF) is the most frequent autosomal recessive disorder in the 
Caucasian population. The responsible gene (CFFR) maps on Cbromosome 7 mad 
since its identification more then 1(~)  mutation were identified. In the general 
population, 1 : 2500 3(~)  l ife newbom is affected, the carrier frequency is estimated 
as 1:25 27 people. Identification of the healthy cmrier in the population remains one 
of the major issue in the potential planning for a genetic based identification of 
couple at risk. Therefore, the maj or a im of the study is to verify, for the first t ime ha 
Italy, the feasibility of testing for CFTR mutations on an italian population sample. 
The study spanned a period over 1995 2CO4. By the set up of a two branch semi 
automated system, we have analysed 42 . (~)  voluntary healthy subjects with no 
family history of CE Among them, 38.0C~) subjects were coupled and ~ single. 
As first branch, all the subjects were analysed by an in house Reverse Dot Blot 
detection test developed for the most frequent 48 mutations ha the literature. 
Subsequently, as second branch, negative partners to RDB were analysed by DGGE 
and eventually sequenced. By these means we were able to assess the frequency of 
CFTR mutations in our sample population, DF508 having a 41.3% frequency. We 
have confirmed that 4% of our sample population was carrier for CF mutations, 
furthermore, we have identified 11 adult subjects compound heterozygote for CF, 
suffering for CBAVD. Moreover, we detected 91 couple at r isk and performed 
prenatal diagnosis on each of them. 
In conclusion, we  can speculate that by coupling RDB and DGEE or DHPLC 
techniques a genetic testing of the general population might be feasible. 
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for rapid sweat testing in patients with Cystic Fibrosis 
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Inr  roduetion: Determination of sweat conductivity with the Nanoduct ® System is 
an alternative to conventional chloride measurements. 
Methods:  With Nanoduct® electrodes conductivity is measured in microprobes 
(>3~tl) on skin and results are available within minutes. We used this test system in 
a partly selected number of children and some adults with or without CF (n 111; 
data from St. Gallen, J. Pediatr 2CO5;146:183 8), ha 49 babies (Beme), and in 
children with symptoms uspected t o have CF (n 119; Berne). 
Results: In 49 babies (median age: 38.5 weeks gest ational ge [GA], range 32.4 to 
43) determinations were done at a median postpartal age [PPA] of 1.4 weeks (range 
0.1 to 21). Conductivity determination was successful in 26 babies (48%). In 230 
subjects (3 weeks to 60 yrs) 21 children had no sweat and 14 insufficient sweat to 
compare Nanoduct® conductivity to conventional chloride. 21 had CF diagnosed 
earlier, all were identified by the Nanoduct®. Ten times the test was not successful 
due to skin problems and 13 times due to other cl inical conditions (post prematurity 
4 x, ha 9 cases no reason or technical problems). In 230 patients older than one 
month Nanoduct ® was not successful in 21 subjects ffailure rate 9 %). In newborns 
and prematures the rate of s~access was lower and significantly associated with GA 
(p 0.003), PPA (p < 0.C~)l), corrected GA (p < 0.C~)l), weight (p 0.002), mad 
body temperature (p 0.012). 
Conclusion: The Nanoduct® system is a simple rapid test for CF. However, in 
prematures and newboms as wel l  as ha more severely il l  children and patients with 
skin problems the fai lure rate is higher than previously assumed. 
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Aims:  Nasal Potential Difference (NPD) measurement has been advocated as a 
diagnostic" tool for CF patients with unusual manifestations and as a method for 
assessing response to new therapies directed at correcting CFTR function. The 
purpose of this study is to examine the reproducibility of nasal potential difference 
measurements. 
Methods:  69 patients aged 16 + 8 years of age (range: 6 52) underwent NPD 
measurements on at least of two occasions. 
Results: 25 patients with classical CF aged 21 + 8 years of age and 44  patients with 
atypical CF aged 14 + 8 years of age underwent repeated NPD measurements. The 
basal PD and the response to amiloride (Aamil) and response to CI free & 
isoproterenol (Achlor) were very similar in both measurements. In the classical CF 
group the values were 40+ 12mV vs. 39 + l lmV (p~).565) for basal PD, 
27 + 9mV vs. 26 + 10mV (p~).549) for Aamil  and 2.1 + 3.8mV vs. 0.4 + 2.9mV 
(p~).069) for Achlor. In the atypical CF group the values were 32 + 13mV vs. 
28 + 10mV (p 0.007), 19 + 10mV vs. 17 + 8mV (p~).358) and 3.2 + 4.6mV vs 
3.3 + 4.4mV (p 0.859), respectively. 
Conclusion:  When performed in a s ingle center, NPD measurement is a 
reproducible t st for CF patients with classical disease and may be a useful outcome 
measurement for assessment of efficacy of new treatments. In patients with atypical 
disease basal PD may vary. This might follow the variability in sweat chloride 
concentration observed previously. 
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Sweat conductivity and quantitative pilopcarpine iontophoresis tests 
for sweat chloride 
S. Salomonsson, B.M. Jakobsson, L. Hje l te 
Stockholm CF Center; Karolinska University Hospital Huddinge, Stockhohn, 
Sweden 
Sweat testing has been the most widely used d ia~ost ic  test for cystic fibrosis for 
almost 50 years. The role of conductivity in definit ive CF d ia~os is  has still to be 
confirmed. 
Objective: To compare the quantitative pilocarpine iontophoresis test for sweat 
chloride with the Nanoduct conductivity system. 
Su&jects:Subjects(n 234) with cl inical s'uspicion of CF referred for sweat est were 
consecutively tested. The subjects were divided into 9 groups by age (0 6 m, 
7 12m,  1 2y,  36y ,  7 12y, 13 18y, 1930y ,  31 50y ,>51y) .  
Methods: Sweat tests were performed using the Nanoduct conductivity system and 
the standard Gibson and Cooke technique of pi locarpine ionthophoresis 
simultaneously on the right and left arm, respectively, or on one arm and on the 
back. Those with a chloride concentration > 60 mmol/L were considered as CF 
patients (n 11). 
Results: The correlation between sweat chloride mad conductivity was r~).67 
(p<0.C~)l). The conductivity mean values ha non CF subjects were for each age 
group: 28, 33, 32, 35, 36, 35, 40, 39, 42 and the mean chloride concenlr ation ones 
were: 14, 16, 20, 17, 17, 17,21, 23, 27. Of  the 11 CF patients f ive showed a chloride 
concentration value above the conductivity one. Furthermore, of those with chloride 
concentrations < 60 mmol/L 14 showed values above the conductivity one, 10 of 
whom being < 3 years of age. In four of the 14 subjects borderline values would 
have been missed and in one case possibly a CF diagnosis. 
CotwIusion: The sweat conductivity method showed good correlation with the 
quantitative pilc~arpine iontophoresis test for sweat chloride. However, before 
being used as a screening or confirmative method more data is needed concerning 
cases with higher sweat chloride concentrations than conductivity values. 
